Recombinant human erythropoietin (rHuEPO) in combination with chemotherapy increases breast cancer metastasis in pre-clinical mouse models

نویسندگان

  • Benjamin D. Hedley
  • Jenny E. Chu
  • D. George Ormond
  • Michel S. Beausoleil
  • Alexandra Boasie
  • Alison L. Allan
  • Anargyros Xenocostas
چکیده

This work was supported by funding from Janssen-Ortho Canada and the London Regional Cancer Program (ALA and AX); and by a grant from the Canada Foundation for Innovation (#13199) (ALA). JEC is supported by graduate scholarships from the National Sciences and Engineering Council, the Canadian Institutes for Health Research (CIHR) Strategic Training Program and the Translational Breast Cancer Research Unit, London Regional Cancer Program. ALA is supported by a CIHR New Investigator Award and an Early Researcher Award from the Ontario Ministry of Research and Innovation.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Recombinant human erythropoietin in combination with chemotherapy increases breast cancer metastasis in preclinical mouse models.

PURPOSE Erythropoiesis-stimulating agents (ESA) are used clinically for treating cancer-related anemia. Recent clinical trials have reported increased adverse events and reduced survival in ESA-treated breast cancer patients receiving chemotherapy, potentially related to erythropoietin (EPO)-induced cancer progression. However, minimal preclinical data are available about the impact of EPO on m...

متن کامل

Cancer Therapy: Preclinical Recombinant Human Erythropoietin in Combination with Chemotherapy Increases Breast Cancer Metastasis in Preclinical Mouse Models

Purpose: Erythropoiesis-stimulating agents (ESA) are used clinically for treating cancer-related anemia. Recent clinical trials have reported increased adverse events and reduced survival in ESA-treated breast cancer patients receiving chemotherapy, potentially related to erythropoietin (EPO)-induced cancer progression. However, minimal preclinical data are available about the impact of EPO on ...

متن کامل

The Efficacy of Recombinant Human Erythropoietin in Treatment Chemotherapy Induced Anemia in Children Diagnosed with a Solid Cancer

Background Recombinant human erythropoietin (rHuEPO) treatment can increase hemoglobin levels and decrease transfusion requirements. This study aims to investigate how blood transfusion influences Hemoglobin levels in patients receiving rHuEPO for 12 weeks. Materials and Methods This was a case-control study of 60 patients less than 15 years with anemia and a solid tumor in any location betw...

متن کامل

Recombinant Human Erythropoietin in Children with Solid Tumors and Chemotherapy-induced Anemia

Background: In patients undergoing chemotherapy for cancer, anemia is part of the progression of the disease. Considering the effects of anemia on quality of life of the patients, the prevention and treatment of chemotherapy-induced anemia is crucial. This study was aimed to evaluate the efficacy of recombinant human erythropoietin in reducing the need for blood transfusion in children with sol...

متن کامل

Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models.

We investigated the significance of erythropoietin receptor (EPOR) expression following treatment with recombinant human erythropoietin (rHuEPO; epoetin alpha) and the effect of recombinant epoetins (epoetin alpha, epoetin beta, and darbepoetin alpha) alone or in combination with anticancer therapy on tumor growth in two well-established preclinical models of breast carcinoma (MDA-MB-231 and MC...

متن کامل

ذخیره در منابع من

ذخیره در منابع من قبلا به منابع من ذحیره شده

{@ msg_add @}


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:

دوره   شماره 

صفحات  -

تاریخ انتشار 2011